financetom
Business
financetom
/
Business
/
Micron Stock Is Rising Tuesday: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Micron Stock Is Rising Tuesday: Here's Why
Jun 3, 2025 11:32 AM

Micron Technology Inc. ( MU ) shares are trading higher Tuesday after the company announced it has started shipping qualification samples of its latest low-power memory product.

What To Know: The company’s new LPDDR5X memory is based on Micron’s 1-gamma node, which is one of the most advanced process technologies currently in development for DRAM. It is designed to support high-speed, low-power data handling in mobile devices, particularly those integrating artificial intelligence functions.

Micron said the memory is intended for use in flagship smartphones, where AI-driven features like image recognition, language processing and on-device machine learning require faster and more efficient memory. By beginning the sampling process, Micron is signaling that the product is nearing commercial readiness, allowing phone makers to begin validation and testing for potential inclusion in upcoming models.

The announcement comes as AI features are becoming increasingly prevalent in premium consumer devices, and memory performance remains a key bottleneck. The 1-gamma node offers improvements in density, speed and power efficiency, which are critical for battery-powered devices. The market is watching closely to see whether smartphone manufacturers will ramp up production volumes in the second half of 2025 given mixed signals on global demand.

Micron's AI-focused memory adds to ongoing momentum in the semiconductor sector, where companies are racing to meet the technical demands of AI applications across consumer, enterprise and industrial markets. For Micron, the LPDDR5X update serves to strengthen its position in the mobile segment, though broader market conditions and adoption timelines will determine how significantly this product contributes to near-term revenue.

MU Price Action: Micron shares were up 3.55% at $101.67 at the time of publication Tuesday, according to Benzinga Pro.

Read Next:

EXCLUSIVE: May’s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved